🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

at Fairmont Le Château Frontenac facebook.com/1198773050/pos…

at À Québec, Canada. facebook.com/1198773050/pos…

in Quincy facebook.com/1198773050/pos…

ASCO 다들 오셨는데 얼굴이라도 봐야죠 — in Chicago facebook.com/1198773050/pos…

Not sure how I ended up here — at House of Blues Chicago facebook.com/1198773050/pos…

at CHICAGO CUT STEAKHOUSE facebook.com/1198773050/pos…

in Washington facebook.com/1198773050/pos…

at facebook.com/1198773050/pos…

traveling to London, United Kingdom from Boston Logan International Airport facebook.com/1198773050/pos…

in London, United Kingdom facebook.com/1198773050/pos…

in Paris facebook.com/1198773050/pos…

한달만에 온 로마. 서로 왜 모였는지 잘 모르는 모임. — in Rome facebook.com/1198773050/pos…

왜 왔는지 아직도 모름

Inaugural gathering of AAPI physicians from MGH/MGPO/MEEI who manage oncology. Aimed at building networks, navigating bias, supporting others, promoting professional development. At Seoul Restaurant, Boston, MA. #StrongerTogether #StopAAPIHate

Neoadjuvant immunotherapy of locoregionally advanced solid tumors jitc.bmj.com/content/10/8/e… I like HNSCC part which addresses safety concerns of potentially compromising curative therapy and provides some guidance in study design. Still this will remain major huddle in WOO trials

Looking forward to presenting during the annual Mass General Cancer Center’s Advances in Cancer Immunotherapy CME on May 1-2! Learn more & register: tinyurl.com/4duajbdj Mass General Brigham Professional Development

A rapidly growing # of HPV-targeted Rx are coming to clinical phase. Is robust activity possible w vaccine? What modality? what combo? too many Qs. I organized my thoughts here Current Status of HPV–Targeted Therapies Development in Head and Neck Cancer ascopubs.org/doi/10.1200/PO…

Bring back McDonald #ASCO #ASCO2024

Will ADC have a position in head and neck cancer treatment paradigm? ascopubs.org/doi/pdf/10.120… My take on #ADC in #HNSCC

KN689 update. Any advance in HNSCC is great, and this is undoubtedly encouraging. But wonder what the tolerance/comfort level of surgeons or med onc is for single agent pembro x 2 (and delaying surgery) in curative population. Uppaluri group proved feasibility but interesting to